AC Immune SA (ACIU), a clinical-stage biopharmaceutical company, on Friday released new preliminary data from the Phase 1 trial for the TDP43-PET tracer ACI-19626, indicating higher uptake in patients of amyloid lateral sclerosis (ALS). The data was presented at the 2026 Summit Advancing TDP43 Biomarkers hosted by the University of Wisconsin.
TDP-43 is the main component in inclusions found in the brains of patients suffering from certain neurodegenerative disorders like frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), limbic-predominant age-related TDP-43 encephalopathy (LATE), and co-pathologies of Alzheimer's and Parkinson's disease. The diagnosis of these diseases is complex due to the absence of reliable biomarkers. TDP-43 is being explored as a biomarker to specifically diagnose neurological proteinopathies.
The ACI-19626 tracer enables visualization of the TDP-43 markers in the brain using Positron Emission Tomography (PET) scanning.
The ongoing Phase 1 trial for ACI-19626 consists of Part 1, conducted on healthy patients, and Part 2, enrolling up to 30 patients with FTD, ALS, and LATE. Preliminary results suggest a higher uptake of the tracer in patients with ALS, validated with released PET data.
The study has also established a pharmacokinetic profile of ACI-19626, confirming its suitability in human brain imaging.
ACIU closed Friday at $2.83, down 0.70%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.